Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Brepocitinib in Renal Impairment
NCT04260464Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brepocitinib in plaque psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and 3 more (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration of PF-06700841, Area Under the Concentration-time Curve From Time 0 to Infinity of PF-06700841 and 2 more. Started Jul 2020; status: completed.
02
Drugs
brepocitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)systemic lupus erythematosus (SLE)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04260464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260464.